Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 8/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | RAD52 | P43351 | 2/20 | 0.53 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19475235 | 0.85 | ADORA1 (0.81) | ADORA1KMT2AMEN1MAPTGAA | |
| SCHEMBL19475245 | 0.83 | MAPK1 (0.68) | KMT2AMEN1MAPTGAAKDM4E | |
| SCHEMBL19475083 | 0.80 | ADORA1 (0.67) | ADORA1KMT2AMEN1MAPTGAA | |
| SCHEMBL19475192 | 0.76 | MAPT (0.66) | ADORA1KMT2AMEN1MAPTGAA | |
| SCHEMBL4709539 | 0.73 | MAPT (1.00) | ADORA1KMT2AMEN1MAPTGAA | |
| SCHEMBL10862455 | 0.73 | MAPT (0.80) | ADORA1KMT2AMEN1MAPTGAA | |
| SCHEMBL17018755 | 0.73 | MAPT (0.80) | ADORA1KMT2AMEN1MAPTGAA | |
| SCHEMBL6993930 | 0.71 | MAPT (0.72) | ADORA1KMT2AMEN1MAPTGAA | |
| SCHEMBL1792135 | 0.71 | MAPT (0.66) | MAPTGAAALDH1A1HPGD | |
| SCHEMBL16007300 | 0.70 | ADORA1 (0.80) | ADORA1KMT2AMEN1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647725-B2 | Anti-infective 2-aminothiophenes | THE UNIVERSITY OF TOLEDO (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190119296-A1 | Anti-Infective 2-Aminothiophenes | THE UNIVERSITY OF TOLEDO (US) | 2019-04-25 | — | — | US | disclosed |
| WO-2017184947-A1 | ANTI-INFECTIVE 2-AMINOTHIOPHENES | THE UNIVERSITY OF TOLEDO (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119296-A1 | Anti-Infective 2-Aminothiophenes | TST, ABAT, TPMT | ADORA1 3371/4885KMT2A 1592/4885MEN1 3808/4885 |
| US-10647725-B2 | Anti-infective 2-aminothiophenes | TST, ABAT, TPMT | ADORA1 3371/4885KMT2A 1592/4885MEN1 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.